| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human,Mouse,Rat |
| Host species | Rabbit |
| Applications | ELISA,WB-Ce |
| Brand: | Abnova |
| Reference: | PAB7913 |
| Product name: | WASF1 (phospho Y125) polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic phosphopeptide of WASF1. |
| Gene id: | 8936 |
| Gene name: | WASF1 |
| Gene alias: | FLJ31482|KIAA0269|SCAR1|WAVE|WAVE1 |
| Gene description: | WAS protein family, member 1 |
| Immunogen: | Synthetic phosphopeptide (conjugated with KLH) corresponding to residues surrounding Y125 of human WASF1. |
| Form: | Liquid |
| Recommend dilutions: | ELISA (1:2000) Western Blot (1:500) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (50% glycerol, 1 mg/mL BSA, 0.05% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Human |
| Specificity: | This sequence has high homology with similar regions in rat and mouse WAVE1, and has less than 50% homology to similar regions in the conserved site in WAVE2 (Tyr-124) and WAVE3 (Tyr-125). |
| Reactivity: | Human,Mouse,Rat |
| Application image: | ![]() |
| Application image note: | Western blot of human SYF cSrc-transformed cells untreated (lane 1) or treated (lane 2) with pervanadate (1 mM; 30 min). The blots were probed with WASF1 (phospho Y125) polyclonal antibody (Cat # PAB7913). |
| Applications: | ELISA,WB-Ce |
| Shipping condition: | Dry Ice |
| Publications: | Identification of two human WAVE/SCAR homologues as general actin regulatory molecules which associate with the Arp2/3 complex.Suetsugu S, Miki H, Takenawa T. Biochem Biophys Res Commun. 1999 Jun 24;260(1):296-302. |